
FDA Approves Nasal Powder to Treat Migraines
Satsuma Pharmaceuticals, Inc. announced that the FDA has approved a 505(b)(2) New Drug Application (NDA) for Atzumi™(dihydroergotamine (DHE)) nasal powder for the acute treatment of migraine with or without aura in adults. Atzumi was previously known as …